Perioperative outcomes and lymph node assessment after induction therapy in patients with clinical N1 or N2 non-small cell lung cancer

Glover, J.; Velez-Cubian, Frank O.; Toosi, Kavian; Ng, Emily; Moodie, Carla; Garrett, Joseph; Fontaine, Jacques; Toloza, Eric M.

doi:10.21037/jtd.2016.07.09

Cited by 15 publications

(21 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In spite of lacking multicenter prospective researches, a large number of retrospective studies proved that neoadjuvant chemotherapy did not add any extra risk to the occurrence of perioperative complications and mortality [7, 26, 27] even though mediastinal structures become differently affected after neoadjuvant chemotherapy. In addition, the optimal interval time from the end of neoadjuvant chemotherapy to surgery was proven to be not more than 6 weeks [28].…”

Section: Discussionmentioning

confidence: 99%

Video assisted thoracic surgery vs. thoracotomy for locally advanced lung squamous cell carcinoma after neoadjuvant chemotherapy

Fang

Wang

et al. 2018

J Cardiothorac Surg

View full text Add to dashboard Cite

BackgroundSurgery is an important part of multidisciplinary treatment strategy for locally advanced lung squamous cell carcinoma (LSCC), but insufficient evidence supports the feasibility and safety of video assisted thoracic surgery (VATS) following neoadjuvant chemotherapy for locally advanced LSCC. This study aims to compare perioperative data and long-term survival of locally advanced LSCC patients between VATS and thoracotomy after neoadjuvant chemotherapy.MethodsWe retrospectively collected the clinical and pathological information of patients with locally advanced LSCC who underwent surgical resection after neoadjuvant chemotherapy from October 2013 to October 2017. All patients were divided into two groups (thoracotomy and VATS) and were compared the differences in perioperative, oncological and survival outcomes.ResultsA total of 81 patients were analyzed in this study (67 thoracotomy and 14 VATS). VATS provided less postoperative pain (P = 0.005) and produced less volume of chest drainage (P = 0.019) than thoracotomy, but the number of resected lymph nodes was less in VATS group (P = 0.011). However, there was no significant difference in the number of resected lymph node stations and the rate of nodal upstaging between two groups. The mean disease free survival (DFS) was 32.7 ± 2.7 months for the thoracotomy group and 31.8 ± 3.0 months for the VATS group (P = 0.335); the corresponding overall survival (OS) was 41.7 ± 2.2 months and 36.4 ± 4.1 months (P = 0.925).ConclusionIn selected patients with locally advanced LSCC, VATS played a positive role in postoperative recovery and associated similar survival outcome compared with thoracotomy after neoadjuvant chemotherapy.

show abstract

Section: Discussionmentioning

confidence: 99%

Video assisted thoracic surgery vs. thoracotomy for locally advanced lung squamous cell carcinoma after neoadjuvant chemotherapy

Fang

Wang

et al. 2018

J Cardiothorac Surg

View full text Add to dashboard Cite

show abstract

“…There was substantial variability in operative time, and our mean duration of 227 minutes for lobectomy is on par with the majority of postinduction cases in the literature. For instance, Glover et al report an operative time for lobectomy of 264 minutes in patients who have undergone chemotherapy and 257 minutes in patients who have undergone chemoradiation, compared with 203 minutes in patients who did not receive induction treatment (18). In the current study, conversion to thoracotomy was required in 1 of the 5 anatomic resections attempted via a minimally invasive approach (20%).…”

Section: Commentmentioning

confidence: 99%

Safety and Feasibility of Lung Resection After Immunotherapy for Metastatic or Unresectable Tumors

Bott

Cools-Lartigue

Tan

et al. 2018

The Annals of Thoracic Surgery

112

101

View full text Add to dashboard Cite

show abstract

“…These results imply that the risk of PE in lung cancer patients receiving nonsurgical therapy is higher than those only undergoing lung resection. Furthermore, the overall frequency of PE in patients undergoing video-assisted thoracoscopic surgery (VATS) or robotic-assisted video thoracoscopic surgery (RAVTS) for lung cancer is 0.5% varying between 0 and 2% 26 , 27 , 29 , 34 , 37 , 45 , implying VATS or RAVTS is feasible in lung cancer.…”

Section: Incidence Of Pe In Lung Cancer Patientsmentioning

confidence: 99%

“…The majority of patients were male (15,754, 61.4%) and the mean age was 62.5 years, ranging from 19 to 93 11 , 13 - 24 , 26 , 28 , 29 , 31 - 41 , 43 - 45 , 47 - 51 . We also found that major patients only receiving surgery for lung cancer had stage I/II but those receiving nonsurgical conditions had stage III/IV according to table 2 , which might be one of causes of higher rate of PE in lung cancer patients with nonsurgical therapy.…”

Section: Incidence Of Pe In Lung Cancer Patientsmentioning

confidence: 99%

Lung Cancer and Pulmonary Embolism: What Is the Relationship? A Review

Shang²,

Wang

et al. 2018

J. Cancer

View full text Add to dashboard Cite

Pulmonary embolism (PE) is gradually considered to be the third most common disease in the vascular disease category. Lung cancer is the most frequently diagnosed cancer and the leading cause of cancer death among males worldwide. Although initially appearing as distinct entities, lung cancer is a great risk factor for the development of PE. Pulmonary embolism is common in lung cancer patients, with a pooled incidence of 3.7%, and unsuspected pulmonary embolism (UPE) is also non-negligible with a rough rate ranging from 29.4% to 63%. Many risk factors of PE have been detected and could be classified into three categories: lung cancer-related, patient-related, and treatment-related factors. Decreased mean survival time could be significantly observed in lung cancer patients with PE or UPE compared to those only, but suspected PE has higher mortality than UPE. Prophylactic anticoagulant therapy benefit might be highest in patients with stage IV non-small cell lung cancer (NSCLC) or limited small cell lung cancer (SCLC), and heparin seems superior to warfarin for thrombotic prophylaxis. Periodically reassessing the risk-benefit ratio of anticoagulant treatment will be an efficient treatment strategy in lung cancer patients with PE.

show abstract

Perioperative outcomes and lymph node assessment after induction therapy in patients with clinical N1 or N2 non-small cell lung cancer

Cited by 15 publications

References 20 publications

Video assisted thoracic surgery vs. thoracotomy for locally advanced lung squamous cell carcinoma after neoadjuvant chemotherapy

Video assisted thoracic surgery vs. thoracotomy for locally advanced lung squamous cell carcinoma after neoadjuvant chemotherapy

Safety and Feasibility of Lung Resection After Immunotherapy for Metastatic or Unresectable Tumors

Lung Cancer and Pulmonary Embolism: What Is the Relationship? A Review

Contact Info

Product

Resources

About